Skip to main content

Table 1 Clinical data of patients included in this study

From: Chromatin accessibility landscapes of immune cells in rheumatoid arthritis nominate monocytes in disease pathogenesis

  Blood samples for ATAC-seq libraries Blood samples for FACS analysis Blood samples for CRP stimulation
RA patients OA patients RA patients OA patients OA patients
Number of patients 26 23 8 5 8
Gender, F/M 21/5 19/4 8/0 3/2 4/4
Age (years) 54 (48–66) 61 (54–67) 54.5 (49.5–68.75) 61 (57–62) 65 (62–67.75)
RF positive (%) 76.9 0 75 0 0
Anti-CCP positive (%) 73.1 NA 87.5 NA NA
TCJ 10 (3–12) NA 11 (4.75–14) NA NA
SCJ 10 (4–12) NA 10 (3.5–11.5) NA NA
GH 70 (50–80) NA 75 (50–80) NA NA
ESR 30 (16–42) 11 (10–14.75) 29.5 (15.75–46.75) 14 (8–19) 8 (6–18.5)
CRP 22.9 (6.8–44.3) 3.13 (3.13–3.14) 30.22 (6.75–53.95) 3.11 (3.11–3.12) 3.055 (2.97–7.3)
DAS28-ESR 6 (5–6) NA 6 (4.75–7) NA NA
DAS28-CRP 6 (5–6) NA 6 (5.25–6) NA NA
  1. Values provide the median with IQR
  2. F/M female/male, ESR erythrocyte sedimentation rate, CRP C-reactive protein, RF rheumatoid factor, Anti-CCP anti-cyclic citrullinated peptide, TCJ tender joint count, SCJ swollen joint count, GH patient assessment of disease activity using a 100-mm visual analogue scale (VAS) with 0 = best and 100 = worst, DAS28-ESR Disease Activity Score 28-erythrocyte sedimentation rate, DAS28-CRP Disease Activity Score 28-C-reactive protein, FACS flow cytometry, NA not account